OTC · BIOR
Healthcare · Biotechnology
$0.22
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 8:46 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BIOR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BIOR.
BIOR research
Company profile and research snapshot.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 22, 2024 | HC Wainwright & Co. | Buy | — |
| May 16, 2024 | HC Wainwright & Co. | Buy | — |
| Jan 2, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 28, 2024
Biora Therapeutics announced progress on its BioJet™ Oral Delivery Platform, a swallowable, needle-free autoinjector that can deliver larger drug payloads than other ingestible injectables. The company has reduced the device size while increasing payload capacity and plans to complete testing in 2024-2025.
GlobeNewswire Inc. · Aug 26, 2024
Biora Therapeutics, a biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, where the company will present and hold investor meetings.
GlobeNewswire Inc. · May 15, 2024
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.
GlobeNewswire Inc. · May 7, 2024
The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BIOR.
No results
No recent SID articles mention BIOR.
